Allink Biotherapeutics, a clinical-stage biotech company based in Beijing, raised $42 million in Series A funding.
The company specializes in developing advanced bispecific antibodies and antibody-drug conjugates (ADCs) aimed at improving treatment options in oncology and immunology.
Lanchi Ventures led the investment round with support from Yuanbio Venture Capital, Legend Capital, and C&D Emerging Industry Equity Investment. Existing investors Gaorong Ventures and Med-Fine Capital also participated in this funding round.
Allink Biotherapeutics plans to channel the newly secured funds into several key areas:
- Clinical Development: Advancing its lead therapeutic candidates, ALK201 and ALK202, through Phase 1 clinical trials in Australia, the United States, and China.
- Pipeline Expansion: Adding new, high-potential treatments to its existing portfolio, focusing on competitive assets in the oncology and immunology fields.
- Platform Innovation: Further refining its proprietary technology platforms for bispecific antibodies and ADCs to strengthen its therapeutic offerings.
- Global Reach: Expanding its presence internationally to enhance access to its innovative treatments and collaborations worldwide.
Led by founder and CEO Hui Feng, Ph.D., Allink Biotherapeutics is dedicated to addressing critical unmet needs in oncology and immunology, aiming to shift treatment paradigms and improve patient outcomes globally.